Drugs / ENX-102
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07193563 | Sep 2025 → Mar 2026 | social phobia | Engrail Therapeutics INC | Completed | No outcome recorded |
| Phase 2 | NCT06653296 | Dec 2024 → Jun 2025 | generalized anxiety disorder | Engrail Therapeutics INC | Completed | No outcome recorded |
| Phase 2 | NCT05749055 | Jul 2023 → Sep 2025 | generalized anxiety disorder | Engrail Therapeutics INC | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-07-18 | Engrail Therapeutics INC | Engrail Therapeutics Initiates the ENCALM Phase 2 Clinical Trial of ENX-102 in Patients with Generalized Anxiety Disorder engrail.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENX-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06653296 ↗ |
| Action | Activate | “Selective GABA-A alpha2,3,5 positive allosteric modulator” NCT05749055 ↗ |
| Route | Oral | “taken orally once daily in the evening” NCT05749055 ↗ |